Regeneron Reports registry Data for Rituximab in Psoriasis

Regeneron today announced registry results for rituximab in patients with psoriasis. The study demonstrated that rituximab demonstrates safety and tolerability compared to standard of care or placebo. These results provide important insights into the treatment of psoriasis and support the continued development of rituximab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.